Role, Impact, and Effect of Angiotensin-converting Enzyme 2 (ACE2) in Patients with COVID-19 under High-altitude Conditions
Abstract
Background: A number of studies on the mechanisms of the positive effect of angiotensin (Ang) converting enzyme type 2 (ACE2) on the general condition of patients with coronavirus disease (COVID-19)
reflect its direct correlation with the ACE2 concentration. This study investigated how the high-altitude factor affects angiotensin regulatory systems in patients with COVID-19 in susceptible populations.
Materials and Methods: A prospective cohort study of 335 patients with COVID-19 and concomitant arterial hypertension determined general clinical, immunological, and other parameters of health status. Group I
included 135 patients of both genders with moderate COVID-19 caused by SARS-CoV-2 and moderate arterial hypertension (AH) who refused anti-hypertensive drugs. Losartan was given to 200 patients of both
genders with a laboratory-confirmed mild SARS-CoV-2 infection and moderate AH in Group II.
Results: Comparing Group II to Group I, the general condition parameters were found to be noticeably improved in Group II. Additionally, patients in Group II showed positive blood coagulation system dynamics. When comparing Groups I and II, the immune response was seen to be more stable in Group II.
Conclusions: Group I patients with ACE2 deficiency set off a chain of events, most of which had to do with how Ang II affected the body by turning on angiotensin type 1 receptors. Observations made in
Group II showed a favourable response to Ang-(1–7) and its effects on angiotensin type 2 receptors, Mas receptors, and the lowering of ACE2 bradykinin, blocking the implementation of the pro-inflammatory
action through B1 receptors.
How to cite this article:
Alymkulov A, Tagaev T, Vityala Y. Role, Impact, and Effect of Angiotensin-converting Enzyme 2 (ACE2)
in Patients with COVID-19 under High-altitude Conditions. J Commun Dis. 2023;55(3):83-89.
DOI: https://doi.org/10.24321/0019.5138.202343
References
Yethindra V. Role of GS-5734 (remdesivir) in inhibiting SARS-CoV and MERS- CoV: the expected role of GS-
(remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis. Int J Res Pharm Sci. 2020;11:1-6. [Google Scholar]
Vityala Y, Tagaev T, Mamatov S, Aidarov Z, Harinath P. Potential effects of itolizumab treatment on plasma
interleukin-6 levels in patients with severe COVID-19. Indian J Pharmacol. 2021;53(3):246-7. [PubMed]
[Google Scholar]
Yethindra V, Tagaev T. Decreased mortality among hospitalized coronavirus disease 2019 patients who
underwent anticoagulant therapy with heparin. Indian J Pharmacol. 2020;52(4):337-8. [PubMed] [Google Scholar]
Yethindra V, Tagaev T, Imankulova A, Kaliev M, Orozalieva B, Niyazalieva M, Zhumabekova A, Kanteti
KP, Kuruva PS. Doxycycline inhibits SARS-CoV-2 replication in vitro. Biomedicine. 2022;42(3):612-5. [Google Scholar]
Kadyrova A, Antipina I, Kyrbasheva I, Baudinov I, Kulbaeva B, Aitieva U, Zhunushaliev C, Vityala Y,
Tagaev T. CT patterns and differential criteria for acuteeosinophilic pneumonia and COVID-19 pneumonia.
Clin Case Rep. 2021;9(10):e04890. [PubMed] [Google Scholar]
Vityala Y, Kadyrova A, Zhumabaeva S, Bazarbaeva A, Mamatov S. Use of B-complex vitamins and olfactory
training for treating COVID-19-related anosmia. Clin Case Rep. 2021;9(11):e05069. [PubMed] [Google Scholar]
Zhumabekova A, Dzhanuzakova N, Chynyeva D, Mambetova M, Niyazalieva M, Vipin, Vityala Y, Tagaev T. Neurological manifestations in pediatric patients with COVID-19: a case series. Biomedicine. 2023;42(6):1380- 2. [Google Scholar]
Vityala Y, Mamytova E, Turgumbaev D, Kadyrova A, Toktomametova A, Zholdoshev E, Karbozova K, Tagaev T, Karthik M, Sandhya K. Clinical features of acute ischemic stroke in moderately and severely ill patients with coronavirus disease 2019 (COVID- 19). Biomedicine. 2021;41(2):397-400. [Google Scholar]
Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8 Suppl(Suppl 1):S9-14. [PubMed] [Google
Scholar]
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, Muller MA, Drosten C, Pohlmann S. SARSCoV- 2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8. [PubMed] [Google Scholar]
Magalhães GS, Rodrigues-Machado MG, Motta-Santos D, Silva AR, Caliari MV, Prata LO, Abreu SC, Rocco
PR, Barcelos LS, Santos RA, Champagnole-Santos MJ. Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol. 2015;172(9):2330-42.
[PubMed] [Google Scholar]
Chen Q, Yang Y, Huang Y, Pan C, Liu L, Qiu H. Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury. J Surg Res. 2013;185(2):740-7. [PubMed] [Google Scholar]
Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, Zhou M, Jiang W. Angiotensin-converting enzyme 2/angiotensin-(1-7)/
Copyright (c) 2023 Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
